Stock Analysis
Med Life (BVB:M) First Quarter 2024 Results
Key Financial Results
- Revenue: RON648.4m (up 22% from 1Q 2023).
- Net income: RON14.5m (up 98% from 1Q 2023).
- Profit margin: 2.2% (up from 1.4% in 1Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Med Life Earnings Insights
Looking ahead, revenue is forecast to grow 10% p.a. on average during the next 2 years, compared to a 5.5% growth forecast for the Healthcare industry in Europe.
Performance of the market in Romania.
The company's shares are up 3.2% from a week ago.
Risk Analysis
You still need to take note of risks, for example - Med Life has 2 warning signs (and 1 which is a bit concerning) we think you should know about.
Valuation is complex, but we're helping make it simple.
Find out whether Med Life is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About BVB:M
Med Life
A private healthcare provider, offers healthcare services in Bucharest, Cluj, Braila, Timisoara, Iasi, Galati, Ploiesti, Constanta, and Targu Mures.
Reasonable growth potential and fair value.